Sfoglia per Autore
Sunitinib-induced hyperparathyroidism: A possible mechanism to altered bone homeostasis
2011 Baldazzi V; Tassi R; Lapini A; Lunghi A; Garofoli E; Caruso S; Carini M; Mazzanti R
Druggable Targets in Pancreatic Adenocarcinoma
2014 Nobili S; Tassi R; Landini I; Perrone G; Napoli C; Mini E
Role of Genetic Polymorphisms on Response to R-CHOP regimen in Diffuse Large B-cell Lymphoma Patients: an Interim Analysis of a Multicenter Prospective Pharmacogenetic Study
2015 Rigacci, L; Perrone, G; Nobili, S; Kovalchuk, S; Puccini, B; Lancia, F; Tassi, R; Brugia, M; Landini, I; Mannelli, L; Benelli, G; Napoli, C; Cencini, E; Fabbri, A; Iovino, L; Petrini, M; Birtolo, S; Melosi, A; Martini, V; Santini, S; Breschi, C; Bernardeschi, P; Bengala, C; Bosi, A; Mini, E
Fluoropyrimidine-related toxicity in gastrointestinal cancer patients. Assessment of risk factors.
2015 Tassi, R; Perrone, G; Brugia, M; Simi, L; Petreni, P; Mori, E; Landini, I; Pazzagli, M; Mazzei, T; Mini, E; Nobili, S
HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment
2015 Garziera, M; Bidoli, E; Cecchin, E; Mini, E; Nobili, S; Lonardi, S; Buonadonna, A; Errante, D; Pella, N; D'Andrea, M; De Marchi, F; De Paoli, A; Zanusso, C; De Mattia, E; Tassi, R; Toffoli, G.
Emerging drugs in refractory colorectal cancer
2015 Nobili, S; Galletta, A; Brugia, M; Tassi, R; Petreni, P; Landini, I; Mini, E
A transcriptomic profile predicts clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy
2016 Mini, E; D’Aurizio, R; Perrone, G; Magi, A; Lapucci, A; Tassi, R; Napoli, C; Picariello, L; Landini, I; Brugia, M; Mazzei, T; Tonelli, F; Nobili, S
Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy
2016 Tassi, R; Mini, E; D'Aurizio, R; Perrone, G; Magi, A; Lapucci, A; Napoli, C; Picariello, L; Brugia, M; Landini, I; Mazzei, T; Tonelli, F; Nobili, S
RNA sequencing reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy
2016 Mini, E.; D’ Aurizio, R.; Perrone, G.; Magi, A.; Lapucci, A.; Tassi, R.; Napoli, C.; Picariello, L.; Landini, I.; Nobili, S.
Adverse drug reactions in oncoLogy: intEnsive monitoring program on drug toXicity of biotechnological medicatioNs anD taRget therapies in Oncologic patientS - the ALEXANDROS observational study
2017 Galiulo M, Convertino I, Blandizzi C, Tassi R, Diacciati S, Nobili S, Capogrosso Sansone A, Marino A, Mini E, Mazzei T, Vannacci A, Parrilli M, Corona T, Tuccori M
Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study.
2017 Rigacci, L; Perrone, G; Nobili, S; Kovalchuk, S; Puccini, B; Tassi, R; Brugia, M; Landini, I; Mannelli, L; Benelli, G; Napoli, C; Cencini, E; Fabbri, A; Iovino, L; Petrini, M; Birtolo, S; Melosi, A; Santini, S; Bernardeschi, P; Bosi, A; Mini, E
THE IMPACT OF GENETIC POLYMORPHISMS ON R-CHOP EFFICACY IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: AN INTERIM ANALYSIS OF A MULTICENTER PROSPECTIVE PHARMACOGENETIC STUDY
2017 S Kovalchuk, L Rigacci, G Perrone, S Nobili, B Puccini, R Tassi, M Brugia, I Landini, L Mannelli, G Benelli, C Napoli, E Cencini, A Fabbri, L Iovino, M Petrini, S Birtolo, A Melosi, S Santini, P Bernardeschi, A Bosi, E Mini
The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways.
2017 Mini, E; Landini, I; Lucarini, L; Lapucci, A; Napoli, C; Perrone, G; Tassi, R; Masini, E; Moroni, F; Nobili, S.
Erratum: The inhibitory effects of HYDAMTIQ, a novel PARP inhibitor, on growth in human tumor cell lines with defective DNA damage response pathways (Oncology Research 25:9 (1441-1451) DOI: 10.3727/096504017X14926854178616)
2018 Mini, Enrico; Landini, Ida; Lucarini, Laura; Lapucci, Andrea; Napoli, Cristina; Perrone, Gabriele; Tassi, Renato; Masini, Emanuela; Moroni, Flavio; Nobili, Stefania
RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy
2019 Mini E.; Lapucci A.; Perrone G.; D'Aurizio R.; Napoli C.; Brugia M.; Landini I.; Tassi R.; Picariello L.; Simi L.; Mancini I.; Messerini L.; Magi A.; Pinzani P.; Mazzei T.; Tonelli F.; Nobili S.
Vinorelbine in non-small cell lung cancer: Real-World data from a single institution experience
2020 Nobili, Stefania; Lavacchi, Daniele; Perrone, Gabriele; Vicini, Giulio; Tassi, Renato; Landini, Ida; Grosso, AnnaMaria; Roviello, Giandomenico; Mazzanti, Roberto; Santomaggio, Carmine; Mini, Enrico
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Sunitinib-induced hyperparathyroidism: A possible mechanism to altered bone homeostasis | 2011 | Baldazzi V; Tassi R; Lapini A; Lunghi A; Garofoli E; Caruso S; Carini M; Mazzanti R | |
| Druggable Targets in Pancreatic Adenocarcinoma | 2014 | Nobili S; Tassi R; Landini I; Perrone G; Napoli C; Mini E | |
| Role of Genetic Polymorphisms on Response to R-CHOP regimen in Diffuse Large B-cell Lymphoma Patients: an Interim Analysis of a Multicenter Prospective Pharmacogenetic Study | 2015 | Rigacci, L; Perrone, G; Nobili, S; Kovalchuk, S; Puccini, B; Lancia, F; Tassi, R; Brugia, M; Landini, I; Mannelli, L; Benelli, G; Napoli, C; Cencini, E; Fabbri, A; Iovino, L; Petrini, M; Birtolo, S; Melosi, A; Martini, V; Santini, S; Breschi, C; Bernardeschi, P; Bengala, C; Bosi, A; Mini, E | |
| Fluoropyrimidine-related toxicity in gastrointestinal cancer patients. Assessment of risk factors. | 2015 | Tassi, R; Perrone, G; Brugia, M; Simi, L; Petreni, P; Mori, E; Landini, I; Pazzagli, M; Mazzei, T; Mini, E; Nobili, S | |
| HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment | 2015 | Garziera, M; Bidoli, E; Cecchin, E; Mini, E; Nobili, S; Lonardi, S; Buonadonna, A; Errante, D; Pella, N; D'Andrea, M; De Marchi, F; De Paoli, A; Zanusso, C; De Mattia, E; Tassi, R; Toffoli, G. | |
| Emerging drugs in refractory colorectal cancer | 2015 | Nobili, S; Galletta, A; Brugia, M; Tassi, R; Petreni, P; Landini, I; Mini, E | |
| A transcriptomic profile predicts clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy | 2016 | Mini, E; D’Aurizio, R; Perrone, G; Magi, A; Lapucci, A; Tassi, R; Napoli, C; Picariello, L; Landini, I; Brugia, M; Mazzei, T; Tonelli, F; Nobili, S | |
| Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy | 2016 | Tassi, R; Mini, E; D'Aurizio, R; Perrone, G; Magi, A; Lapucci, A; Napoli, C; Picariello, L; Brugia, M; Landini, I; Mazzei, T; Tonelli, F; Nobili, S | |
| RNA sequencing reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy | 2016 | Mini, E.; D’ Aurizio, R.; Perrone, G.; Magi, A.; Lapucci, A.; Tassi, R.; Napoli, C.; Picariello, L.; Landini, I.; Nobili, S. | |
| Adverse drug reactions in oncoLogy: intEnsive monitoring program on drug toXicity of biotechnological medicatioNs anD taRget therapies in Oncologic patientS - the ALEXANDROS observational study | 2017 | Galiulo M, Convertino I, Blandizzi C, Tassi R, Diacciati S, Nobili S, Capogrosso Sansone A, Marino A, Mini E, Mazzei T, Vannacci A, Parrilli M, Corona T, Tuccori M | |
| Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study. | 2017 | Rigacci, L; Perrone, G; Nobili, S; Kovalchuk, S; Puccini, B; Tassi, R; Brugia, M; Landini, I; Mannelli, L; Benelli, G; Napoli, C; Cencini, E; Fabbri, A; Iovino, L; Petrini, M; Birtolo, S; Melosi, A; Santini, S; Bernardeschi, P; Bosi, A; Mini, E | |
| THE IMPACT OF GENETIC POLYMORPHISMS ON R-CHOP EFFICACY IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: AN INTERIM ANALYSIS OF A MULTICENTER PROSPECTIVE PHARMACOGENETIC STUDY | 2017 | S Kovalchuk, L Rigacci, G Perrone, S Nobili, B Puccini, R Tassi, M Brugia, I Landini, L Mannelli, G Benelli, C Napoli, E Cencini, A Fabbri, L Iovino, M Petrini, S Birtolo, A Melosi, S Santini, P Bernardeschi, A Bosi, E Mini | |
| The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways. | 2017 | Mini, E; Landini, I; Lucarini, L; Lapucci, A; Napoli, C; Perrone, G; Tassi, R; Masini, E; Moroni, F; Nobili, S. | |
| Erratum: The inhibitory effects of HYDAMTIQ, a novel PARP inhibitor, on growth in human tumor cell lines with defective DNA damage response pathways (Oncology Research 25:9 (1441-1451) DOI: 10.3727/096504017X14926854178616) | 2018 | Mini, Enrico; Landini, Ida; Lucarini, Laura; Lapucci, Andrea; Napoli, Cristina; Perrone, Gabriele; Tassi, Renato; Masini, Emanuela; Moroni, Flavio; Nobili, Stefania | |
| RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy | 2019 | Mini E.; Lapucci A.; Perrone G.; D'Aurizio R.; Napoli C.; Brugia M.; Landini I.; Tassi R.; Picariello L.; Simi L.; Mancini I.; Messerini L.; Magi A.; Pinzani P.; Mazzei T.; Tonelli F.; Nobili S. | |
| Vinorelbine in non-small cell lung cancer: Real-World data from a single institution experience | 2020 | Nobili, Stefania; Lavacchi, Daniele; Perrone, Gabriele; Vicini, Giulio; Tassi, Renato; Landini, Ida; Grosso, AnnaMaria; Roviello, Giandomenico; Mazzanti, Roberto; Santomaggio, Carmine; Mini, Enrico |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile